Benitec Biopharma (BNTC) Competitors

Ardelyx (NASDAQ:ARDX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Which has more risk and volatility, ARDX or BNTC?

Ardelyx has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Does the MarketBeat Community favor ARDX or BNTC?

Ardelyx received 340 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 65.67% of users gave Benitec Biopharma an outperform vote.

Company	Underperform	Outperform
Ardelyx	Outperform Votes 537 67.46%	Underperform Votes 259 32.54%
Benitec Biopharma	Outperform Votes 197 65.67%	Underperform Votes 103 34.33%

Does the media prefer ARDX or BNTC?

In the previous week, Ardelyx and Ardelyx both had 8 articles in the media. Benitec Biopharma's average media sentiment score of 0.51 beat Ardelyx's score of 0.41 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Benitec Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ARDX or BNTC more profitable?

Benitec Biopharma has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-11.73%	-24.87%	-10.51%
Benitec Biopharma	N/A	-44.61%	-41.25%

Do insiders and institutionals hold more shares of ARDX or BNTC?

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 5.9% of Ardelyx shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts rate ARDX or BNTC?

Ardelyx currently has a consensus price target of $10.61, suggesting a potential upside of 128.69%. Benitec Biopharma has a consensus price target of $24.71, suggesting a potential upside of 80.66%. Given Ardelyx's higher probable upside, equities analysts plainly believe Ardelyx is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Which has stronger valuation and earnings, ARDX or BNTC?

Benitec Biopharma has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$333.62M	3.32	-$39.14M	-$0.16	-29.00
Benitec Biopharma	$80K	4,010.12	-$21.75M	-$1.51	-9.06

Summary

Ardelyx beats Benitec Biopharma on 10 of the 17 factors compared between the two stocks.